Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose

References

• BRADFORD, M. M., 1976, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein—dye binding. Analytical Biochemistry, 72,248–254.
   PubMed Web of Science ®Google Scholar
• BROOKMAN, L. J., ROLAN, P. E., BENJAMIN, I. S., PALMER, K. R., WYLD, P. J., LLOYD, P., FLESCH, G., WALDME1ER, F., SIOUFI, A. and MuLuNs, F., Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology and Therapeutics (submitted).
   Google Scholar
• BRUNNER, L. A., POWELL, M. L., DEGEN, P. and FLESCH, G., 1994, A semiautomated analyticalmethod for the determination of potential antihypertensive agents (CGP 48933 and/or CGP 48369) in human plasma using high-performance liquid chromatography. Laboratory Robotics and Auto-mation, 6, 171–179.
   Google Scholar
• BUHLMAYER, P., FURET, P., CRESCIONE, L., DE GASPAR°, M., WHETEBREAD, S., SCHMIDUN, T., LATTMANN, R. and WOOD, J., 1994, Valsartan, a potent orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorganic and Medicinal Chemistry Letters, 4, 29–34.
   Google Scholar
• BUHLMAYER, P., OSTERMAYER, F. and S CHMIDLIN, T., Acyl Compounds. European Patent 443983 (Ciba-Geigy).
   Google Scholar
• CRESCIONE, L., BRADLEY, W. A., BUHLMAYER, P., WHTTEBREAD, S., GLAZER, R., LLOYD, P., MULLER, P. and DE GASPAR°, M., 1995, Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovascular Drug Reviews, 13,230–250.
   Google Scholar
• CRESCIONE, L., DE GASPAR°, M., BUHLMAYER, P., WHTTEBREAD, S., RAMJOUE., H. P. R. and WOOD, J., 1993, Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT -receptor subtype. British Journal of Pharmacology, 110,761–771.
   Google Scholar
• DE GASPARO, M. and WHTTEBREAD, S., 1995, Binding of valsartan to mammalian angiotensin AT, receptors. Regulatory Peptides, 59, 303–311.
   PubMedGoogle Scholar
• DE LEAN, A., MUNSON, P. J. and RODBARD, D., 1978, Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curve. American Journal of Physiology, 40, 360–367.
   Google Scholar
• FLESCH, G., MULLER, P., HL, F., DEGEN, P., HOWALD, H. and DIETERLE, W., 1996, Absolute oral bioavailability of valsartan in healthy volunteers. Abstract of a poster presented at the 6th European Congress on Biopharmaceutics and Pharmacokinetics, Athens, April 1996. European Journal of Drug Metabolism and Pharmacokinetics (special issue), 34.
   Google Scholar
• HELBERGER, J. H., 1936, Ober das Verhalten des Lavulinsaurechlorids und der Acetyllavulinsaure bei der Friedel- Craftsschen Reaktion. Annalen, 522,269–277.
   Google Scholar
• HUSKEY, S.-E., MILLER, R. R. and Cmu-, S. H. L., 1993, N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys and humans. Drug Metabolism and Disposition, 21, 792–799.
   PubMed Web of Science ®Google Scholar
• KANDA, Y., ARAI, H., ASHIZAWA, T., MOREVIOTO, M. and KASAI, M., 1992, New potent mitomycin derivatives: synthesis and antitumor activity of 7,7-(ethylenedioxy)mitomycins. Journal of Medicinal Chemistry, 35, 2781–2786.
   PubMed Web of Science ®Google Scholar
• LO, M.-W., GOLDBERG, M. R., MCCREA, J., Lu, H., FURTEK, C. I. and BJORNSSON, T. D., 1995, Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical Pharmacology and Therapeutics, 58, 641–649.
   PubMed Web of Science ®Google Scholar
• MEIER, P. J., 1993, Canalicular membrane transport processes. In Hepatic Transport and Bile Secretion, edited by N. Tavoloni and P. D. Berk (New York: Raven), pp. 587–596.
   Google Scholar
• MEYER, U. A., Arafura, R., BALANT, L. P., BERITLSSON, L., EICHELBAUM, M., GUENTERT, T. W., HENAUER, S., JACKSON, P., LAUX, G., MIKKELSEN, H., PECK, C., POLLOCK, B. G., PRIEST, SJOQWST, F. and DELINI -S TULA, A., 1996, Antidepressants and drug-metabolizing enzymes—expert group report. Acta Psychiatrica Scandinavica, 93, 71–79.
   Google Scholar
• MUNAFO, A., CHRISTEN, Y., NUSSBERGER, J., S HUM, L. Y., BORLAND, R. M., LEE, R. J., WAEBER, B., BIOLLAZ, J. and BRUNNER, H. R., 1992, Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clinical Pharmacology and Therapeutics, 51, 513–521.
   PubMed Web of Science ®Google Scholar
• OUDE ELFFRINK, R. P. J. and JANSEN, P. L. M., 1994, The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacology and Therapeutics, 64, 77–97.
   Google Scholar
• PARKINSON, A., 1996, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24,45–57.
   Web of Science ®Google Scholar
• STEARNS, R. A., MILLER, R. R., Doss, G. A., CHAKRAVARTY, P. K., ROSEGAY, A., GATTO, G. J. and CHIU, S. H. L., 1992, The metabolism of DUP- 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metabolism and Disposition, 20,281–287.
   PubMed Web of Science ®Google Scholar
• STEARNS, R. A., CHAKRAVARTY, P. K., CHEN, R. and CHru, S. H. L., 1995, Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metabolism and Disposition, 23,207–215.
   PubMed Web of Science ®Google Scholar
• WALDMEIER, F., KAISER, G., ACKERMANN, R., FAIGLE, J. W., WAGNER, J., BARNER, A. and LASSETER, K. C., 1991, The disposition of [" C]- labelled benazepril HC1 in normal adult volunteers after single and repeated oral dose. Xenobiotica, 21,251–261.
   PubMed Web of Science ®Google Scholar
• WHIIEBREAD, S., MELE M., KAMBER, B. and DE GASPAR°, M., 1989, Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochemical and Biophysical Research Communication. 163,284–291.
   Google Scholar